Immunic presents data from phase 2 calliper and calvid-1 trials of vidofludimus calcium at the actrims forum 2024

New york , feb. 29, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 calliper and calvid-1 clinical trials of lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), in two poster presentations at the americas committee for treatment and research in multiple sclerosis (actrims) forum 2024, taking place from february 29 to march 2, in west palm beach, fl. "having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious actrims forum is a testament to the strength of the data we have generated," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking